Volume 18, Number 8—August 2012
Research
VIM-2–producing Multidrug-Resistant Pseudomonas aeruginosa ST175 Clone, Spain
Esther Viedma, Carlos Juan, Jennifer Villa, Laura Barrado, M. Ángeles Orellana, Francisca Sanz, Joaquín R. Otero, Antonio Oliver, and Fernando Chaves
Table A1
Clonal distribution, type of carbapenemase, and drug resistance patterns of MDR Pseudomonas isolates, Spain, January 2007–December 2010 *
| Isolate | No. isolates/y |
Carbapenemase type (no. isolates) | ST | No. (%) resistant isolates |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2007 | 2008 | 2009 | 2010 | PIP/TZ | CAZ | FEP | IMP | MER | ATM | GEN | TOB | AMK | CIP | ||||
| All MDR isolates (183) | 13 | 32 | 38 | 100 | VIM-1, VIM-2, IMP-22, GES1–5 (146) | NA | 92 (50.3)/ 180 (98.4) | 183 (100) | 183 (100) | 183 (100) | 183 (100) | 75 (41.0)/ 179 (97.8)† | 178 (97.3) | 177 (96.7) | 77 (42.1) | 172 (94) | |
| P. aeruginosa (clonal types) | |||||||||||||||||
| B (104) | 0 | 5 | 23 | 76 | VIM-2 (103), IMP-22 (1) | 175, 175 | 21 (20.2)/ 101 (97.1)† | 104 (100) | 104 (100) | 104 (100) | 104 (100) | 14 (13.5)/ 100 (95.2)† | 104 (100) | 104 (100) | 26 (25) | 104 (100) | |
| A (29)‡ | 8 | 16 | 4 | 1 | GES 1/5 (29) | 235 | 29 (100) | 29 (100) | 29 (100) | 29 (100) | 29 (100) | 25 (86.2) | 29 (100) | 26 (89.6) | 25 (86.2) | 28 (96.5) | |
| C (2) | 0 | 0 | 1 | 1 | VIM-2 (2) | NA | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | |
| D (2) | 0 | 0 | 0 | 2 | Noncarbapenemase (2) | NA | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 0 | 2 (100) | 2 (100) | 2 (100) | 2 (100) | |
| Unique clones (40) | 4 | 10 | 8 | 18 | Noncarbapenemase (35) | NA | 31 (88.6)/ 35 (100)† | 35 (100) | 35 (100) | 35 (100) | 35 (100) | 26 (74.3) | 30 (85.7) | 32 (65.7) | 17 (48.3) | 25 (71.4) | |
| 0 | 1 | 0 | 0 | PA_5 VIM-2 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| 0 | 1 | 0 | PA_10 VIM-2 | NA | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| 0 | 0 | 1 | 0 | PA_12 VIM-1 | NA | 4 (80)/ 5 (100)† | 5 (100) | 5 (100) | 5 (100) | 5 (100) | 4 (80) | 5 (100) | 5 (100) | 3 (60) | 5 (100) | ||
| 0 | 0 | 1 | 0 | PA_13 VIM-2 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| 0 | 0 | 0 | 1 | PA_28 VIM-2 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| P. putida (clonal types) | |||||||||||||||||
| Unique clones (6) | 1 | 1 | 2 | 2 | 0 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 1 | 0 | 0 | 0 | PP_1 VIM-2 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| 0 | 1 | 0 | 0 | PP_11 VIM-2 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| 0 | 0 | 1 | 0 | PP_14 VIM-2 | NA | 3 (50)/ 6 (100)† | 6 (100) | 6 (100) | 6 (100) | 6 (100) | 4 (66.6) | 6 (100) | 6 (100) | 2 (33.3) | 6 (100) | ||
| 0 | 0 | 1 | 0 | PP_19 VIM-2 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| 0 | 0 | 1 | 0 | PP25_VIM-1/VIM-2 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| 0 | 0 | 1 | 0 | PP_27 VIM-2 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
*MDR, multidrug resistant; ST, sequence type; PIP/TZ, piperacillin-tazobactam; CAZ, ceftazidime; FEP, cefepime; IMP, imipenem; MER, meropenem; ATM, aztreonam; GEN, gentamicin; TOB, tobramycin; AMK, amikacin; CIP, ciprofloxacin; NA, not available. None of the isolates showed resistance to colistin.
†Percentage drug-resistant isolates when the European Committee on Susceptibility Testing break point was applied.
‡Viedma et al. (16).
